Secondary relevance to vitamin D This paper mainly addresses another topic and also reports a vitamin D analysis, result or scientific synthesis.
This paper mainly addresses another topic and also reports a vitamin D analysis, result or scientific synthesis.
Why this paper is included
Supporting source evidence:
Age and number of months with disease did not correlate with 12, 18, or 24‐month relapse‐free scores (p = 0.41, p = 0.98, p = 0.61, respectively). 14 Younger pemphigus patients appear to experience high rates of relapse, however, the small sample size and rarity of pediatric pemphigus limit the generalizability of these findings. 26 , 27 Other factors that have been associated with triggering pemphigus relapse in smaller scale studies include illicit drug use (cocaine) and viral reactivation (by COVID‐19, herpes simplex virus, cytomegalovirus virus), particularly in immunocompromised patients. 28 , 29 Other known triggers, including thiol drug use, infections, vitamin D deficiency, radiotherapy, pregnancy, trauma, stress, and vaccines, can influence time to relapse. 30
Source: Risk factors for relapse. View original paper
Relevance classification does not establish study quality, causation or editorial approval.
Study design Review / evidence synthesis.
Review / evidence synthesis
Reviews existing research; the exact review methods need further assessment.
Meta-analysis unclear · Blinding not applicable to this review · Research setting awaiting verification
How this paper was classified
Automatic source-based classification; awaiting editorial verification. This is not a quality score.
Publisher article type: review-article
Source: Publisher publication metadata.
What the study types mean
- Systematic review
- Uses explicit methods to identify, assess and summarise research on a defined question.
- Scoping review
- Maps the extent and characteristics of research on a topic.
- Narrative review
- Discusses existing research; systematic-review methods have not been established by this classification.
- Review / evidence synthesis
- Reviews existing research; the exact review methods need further assessment.
- Randomised controlled trial
- Assigns participants or groups to comparison interventions by chance.
- Non-randomised intervention study
- Examines an intervention without random allocation.
- Cohort study
- Examines exposures and outcomes over time within a defined group.
- Case-control study
- Compares people with an outcome against people without it, examining exposures.
- Cross-sectional study
- Examines a population at a particular point in time.
- Observational study
- Observes exposures and outcomes without assigning the exposure; the subtype is not established here.
- Case report
- Describes an individual case.
- Case series
- Describes a group of individual cases.
- Secondary analysis
- Analyses existing study data; this paper is not automatically another independent trial.
- Laboratory study
- Investigates biological processes in a laboratory setting.
- Qualitative study
- Examines experiences or meanings using qualitative methods.
- Genetic instrumental-variable study
- Uses genetic variation as an instrument to investigate relationships; this is not a randomised treatment trial.
- Study protocol
- Describes planned methods and is not evidence that the planned study has reported results.
- Multiple reported designs
- More than one design is explicitly reported; examine the supporting methods.
- Study design awaiting verification
- The available source does not establish a sufficiently clear study design.
Meta-analysis combines numerical results from studies. Blinding describes who was unaware of treatment allocation. Neither is a separate quality grade. Study design, vitamin D relevance and document format are independent filters.
Abstracts
Pemphigus relapse: Mechanisms, risk factors, and agents associated with disease recurrence
Review / evidence synthesis · The Journal of Dermatology · 2024
Original publication title
Pemphigus relapse: Mechanisms, risk factors, and agents associated with disease recurrence
© 2024 The Author(s). The Journal of Dermatology published by John Wiley & Sons Australia, Ltd on behalf of Japanese Dermatological Association.
Original publication · Publisher record · CC BY 4.0
Source wording retained. Formatting, section navigation and display-title punctuation adapted for this research record.
At a glance
What does the authors’ abstract report?
Abstract
Pemphigus represents a spectrum of potentially life‐threatening autoimmune‐mediated skin blistering conditions caused by antibody production against desmoglein 1 and 3 (anti‐DSG 1 and 3) in keratinocytes. Greater than 50% of pemphigus patients experience relapse, which complicates long‐term medical management, including risks associated with re‐treatment and complications such as infection and dehydration. This review aims to elucidate mechanisms, risk factors, and medications associated with pemphigus relapse. Mechanisms of relapse include the persistence of auto‐reactive B‐cell populations post‐treatment and CD20‐ B‐cell populations that reactivate after B‐cell depletion therapy.
Risk factors for relapse include high body surface area (BSA) of pemphigus involvement, high body mass index, high severity according to the Pemphigus Disease Area Index (PDAI) at onset, treatment delay, and high anti‐DSG1 and DSG3 titers post‐treatment. Targeted B‐cell localization is associated with better clinical outcomes, including less frequent relapses. Rituximab is currently the gold standard of treatment for moderate: severe pemphigus and has relapse rates of 11%: 44% in selected studies, with a mean time to relapse of 5.8 months to 36 months following treatment.
Relapse rates across lymphoma dosing (375 mg/m2) versus rheumatoid arthritis dosing (1 g dosing weekly) was inconsistent; however, more frequent dosing, earlier treatment, and higher cumulative dosing were associated with lower relapse rates. Alternative agents that have clinical efficacy include corticosteroid monotherapy, mycophenolate mofetil, azathioprine, and intravenous immunoglobulin. Future studies should include head‐to‐head comparators over long follow‐up periods to identify the best treatment agents associated with the least relapse risk.
Authors’ abstract
Abstract
Pemphigus represents a spectrum of potentially life‐threatening autoimmune‐mediated skin blistering conditions caused by antibody production against desmoglein 1 and 3 (anti‐DSG 1 and 3) in keratinocytes. Greater than 50% of pemphigus patients experience relapse, which complicates long‐term medical management, including risks associated with re‐treatment and complications such as infection and dehydration. This review aims to elucidate mechanisms, risk factors, and medications associated with pemphigus relapse. Mechanisms of relapse include the persistence of auto‐reactive B‐cell populations post‐treatment and CD20‐ B‐cell populations that reactivate after B‐cell depletion therapy.
Risk factors for relapse include high body surface area (BSA) of pemphigus involvement, high body mass index, high severity according to the Pemphigus Disease Area Index (PDAI) at onset, treatment delay, and high anti‐DSG1 and DSG3 titers post‐treatment. Targeted B‐cell localization is associated with better clinical outcomes, including less frequent relapses. Rituximab is currently the gold standard of treatment for moderate: severe pemphigus and has relapse rates of 11%: 44% in selected studies, with a mean time to relapse of 5.8 months to 36 months following treatment.
Relapse rates across lymphoma dosing (375 mg/m2) versus rheumatoid arthritis dosing (1 g dosing weekly) was inconsistent; however, more frequent dosing, earlier treatment, and higher cumulative dosing were associated with lower relapse rates. Alternative agents that have clinical efficacy include corticosteroid monotherapy, mycophenolate mofetil, azathioprine, and intravenous immunoglobulin. Future studies should include head‐to‐head comparators over long follow‐up periods to identify the best treatment agents associated with the least relapse risk.
Publication and source details
Original title: Pemphigus relapse: Mechanisms, risk factors, and agents associated with disease recurrence
Gaurav N. Pathak; Priya Agarwal; Sydney M. Wolfe; Kush H. Patel; Jimmy Dhillon; Babar K. Rao
The Journal of Dermatology · 2024
* CorrespondenceGaurav N. Pathak, Department of Dermatology, Rutgers Robert Wood Johnson Medical School, 1 World's Fair Drive, New Brunswick, NJ 08873, USA.
Email: gnp28@rwjms.rutgers.edu
© 2024 The Author(s). The Journal of Dermatology published by John Wiley & Sons Australia, Ltd on behalf of Japanese Dermatological Association.https://creativecommons.org/licenses/by/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.
Repository JATS snapshot; version as supplied
Source retrieved: 2026-11-11T08:47:33.057185+00:00
DOI: 10.1111/1346-8138.17505 · PMC11624153